The 20-week trial included a 16-week escalation period (where subjects randomised to cagrilintide received progressively increasing doses up to the target dose levels) followed by a 4-week ...

REDEFINE 1 is a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual ...

CagriSema is a fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg and Wegovy. The two molecules promote weight loss by suppressing hunger, enhancing feelings of fullness ...

"I'm happy because if you look at the cagrilintide monotherapy arm (in Novo’s trial), it achieved almost 12% weight loss," Steensberg said. "We see that the low dose (in Novo's trial) of ...